VRCA today
$3.64-$0.08 (-2.11%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourAscending Triangle
15 minStrong Bearish
5 minExpanding
Daily trend turns up above $4.17
Key levels
Resistance$4.61
Resistance$4.17
Support$3.62
Support$3.08
Latest news & SEC filings
EarningsVerrica Pharmaceuticals Posts Q3 2026 Results
SEC FilingVerrica Pharmaceuticals Inc. filed a report on a major company event (Form 8-K)
EarningsVerrica Pharmaceuticals posts Q3 adjusted loss of $0.49 per share, revenue of $6.914M
All VRCA news →About Verrica Pharmaceuticals
Verrica Pharmaceuticals is a therapeutics company focused on treatments for dermatologic diseases. Its commercial product, YCANTH, is an FDA-approved topical therapy for molluscum contagiosum in adults and children aged two and older, sold in the United States through dermatologists, pediatricians, and other health care providers. The company is also developing YCANTH for common warts and VP-315, an injectable oncolytic peptide, for basal cell carcinoma. It operates in the U.S. and has licensed rights in Japan to Torii Pharmaceutical.
Based on the company's 10-K filed Mar 11, 2026.
Nasdaq · Healthcare
Verrica Pharmaceuticals Inc. (VRCA)
What Is the Price Target for VRCA?
SEPT Low Target
$12.00
SEPT Mid Target
$12.00
SEPT High Target
$12.00
Analyst Consensus
$12.00
Is VRCA a Buy or Sell Right Now?
Thesis
- •Revenue growing 370.2% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for VRCA.
Start Free Trial →Is VRCA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$9.13
24
Moat Score
NONE
5/9
Piotroski Score
-8.1
Altman Z-Score
What Is Smart Money Doing with VRCA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →VRCA Growth Story
Revenue YoY
370.2%
3yr Revenue CAGR
57.9%
EPS Growth YoY
88.63%
FCF Growth YoY
71.1%
Revenue Trend
ACCELERATING
Dark Pool Trades for VRCA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for VRCA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:51:25 | $3.98 | 2,071 | $$8K | SELL |
| 18:13:39 | $4.00 | 14,683 | $$59K | SELL |
| 17:38:33 | $4.07 | 1,000 | $$4K | SELL |
| 17:05:47 | $4.20 | 1,000 | $$4K | BUY |
| 22:29:09 | $3.98 | 4,892 | $$19K | BUY |
5 dark pool trades shown · $$95K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for VRCA
PREVIEWSEPT Investing provides real-time options flow tracking for VRCA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $4 | Mar 19 | 126 | $$110 | 1 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Verrica Pharmaceuticals Inc. (VRCA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →VRCA — frequently asked questions
What is VRCA stock price today?
Verrica Pharmaceuticals Inc. (VRCA) is at $3.64, down 2.11% (-$0.08) at the Nov 13, 2026 close.
Why is VRCA stock moving today?
Latest VRCA news — Nov 13, 2026: Verrica Pharmaceuticals Posts Q3 2026 Results · Nov 12, 2026: Verrica Pharmaceuticals Inc. filed a report on a major company event (Form 8-K)
What is the VRCA price target?
The average analyst price target for VRCA is $12.00, ranging from $12 to $12, based on 1 analysts.
What do analysts rate VRCA?
Analyst ratings for VRCA: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did VRCA beat earnings?
VRCA last reported on Aug 6, 2026: EPS -$0.62 vs -$0.39 expected — a miss of 60.0%.
Does VRCA pay a dividend?
VRCA does not currently pay a dividend.
What are VRCA support and resistance levels?
Support: $3.62, $3.08. Resistance: $4.17, $4.61, $5.04.
What are insiders doing with VRCA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on VRCA?
Nov 13, 2026: Verrica Pharmaceuticals Posts Q3 2026 Results · Nov 12, 2026: Verrica Pharmaceuticals Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: Verrica Pharmaceuticals posts Q3 adjusted loss of $0.49 per share, revenue of $6.914M